期刊文献+

流式技术检测外周血白血病细胞在AML复发监测中的应用

Application of flow cytometry for detection of peripheral blood leukemic cells in monitoring of recurrence of acute myeloid leukemia
下载PDF
导出
摘要 目的探讨多参数流式技术(FCM)检测外周血白血病细胞在急性髓细胞白血病(AML)复发监测中的临床应用价值。方法选择2012年1月至2014年6月我院血液科收治的56例AML患者,于首次诱导化疗结束、巩固化疗6个月、巩固化疗12个月应用FCM定期检测患者外周血标本,同时检测骨髓细胞形态学的变化。MRD≥0.01%为MRD阳性,否则为MRD阴性。AML患者首次诱导化疗结束后外周血MRD水平分为高(MRD≥10-2)、中(10-2<MRD<10-4)、低(MRD≤10-4)三个水平。采用χ2检验方法比较首次诱导化疗结束、巩固化疗6个月、巩固化疗12个月的MRD阳性组和MRD阴性组复发率差异,同时比较首次诱导化疗结束后外周血MRD高、中、低三组复发率差异。结果 FCM检测外周血MRD阳性组在首次诱导化疗结束、巩固化疗6个月、巩固化疗12个月的复发率分别为72.7%、89.3%、93.8%,MRD阴性组分别为25.0%、18.1%、0;MRD阳性组与MRD阴性组相比较,首次诱导化疗结束(χ2=7.240,P=0.007)、巩固化疗6个月(χ2=15.554,P=0.000)、巩固化疗12个月(χ2=19.562,P=0.000)三个时间点的复发率差异均有统计学意义(P<0.05);首次诱导化疗结束后外周血MRD高水平组的复发率明显高于中水平组(χ2=8.207,P=0.004)、低水平组(χ2=14.667,P=0.000),差异有统计学意义(P<0.05)。中水平组的复发率与低水平组比较差异无统计学意义(χ2=1.398,P=0.237>0.05)。结论 FCM检测外周血白血病细胞对诊断AML复发及指导个体化治疗有重要意义。 Objective To investigate the application of multi-parameter flow cytometry(FCM) for detection of peripheral blood leukemic cells in monitoring of recurrence of acute myeloid leukemia(AML). Methods Fifty-six patients with AML from January 2012 to June 2014 in Department of Hematology in our hospital were enrolled. Peripheral blood samples of the patients were detected using FCM regularly after the first induction chemotherapy, 6months, 12 months of consolidation chemotherapy. Changes in morphology of bone marrow cell were detected.MRD≥0.01% was defined as MRD positive, and MRD〈0.01% was defined as MRD negative. MRD levels of AML patients after the first induction chemotherapy were divided into high level(MRD≥10-2), medium level(10^-2〈MRD〈10^-4), low level(MRD≤10^-4). Chi square test was used to compare the recurrence rates between MRD positive group and MRD negative group after the first induction chemotherapy, 6 months, 12 months of consolidation chemotherapy.At the same time, the recurrence rates were compared between high level, medium level, low level group after the first induction chemotherapy. Results The recurrence rates after the first induction chemotherapy, 6 months, 12 months of consolidation chemotherapy were 72.7%, 89.3%, 93.8% in MRD positive group, 25%, 18.1%, 0% in MRD negative group, with statistically significant difference between the MRD positive group and MRD negative group after induction chemotherapy(χ^2=7.240, P=0.007), 6 months of consolidation chemotherapy(χ^2=15.554, P=0.000) and 12 months of consolidation chemotherapy( χ^2=19.562, P=0.000), P〈0.05. After the first induction chemotherapy, the recurrence rate in MRD high level group was significantly higher than that in the medium level group( χ^2=8.207, P=0.004) and low level group(χ^2=14.667, P=0.000), and the difference was statistically significant(P〈0.05). There was no statistically significant difference in the the recurrence rate between the medium level group and low level group(χ^2=1.398, P=0.237〉0.05). Conclusion FCM detection of Leukemia cells in peripheral blood has important significance for the diagnosis of recurrent AML and guiding individual treatment.
出处 《海南医学》 CAS 2015年第4期529-531,共3页 Hainan Medical Journal
基金 广州市番禺区科技和信息化局科技计划项目(编号:2012-Z-03-04)
关键词 流式技术 外周血 白血病细胞 复发 Flow cytometry Peripheral blood Leukemic cells Recurrence
  • 相关文献

参考文献8

  • 1Al-Mawali A, Gillis D, Lewis I, et al. The role of mulfiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia [J]. Am I Clin Pathol, 2009, 131: 16-26.
  • 2Arber DA, Brunning RD, Le Beau MM, et al. Acute myeloid leuke- mia and related precursor neoplasms [M]//WHO classification of tu- mours of the haematopoietic and lymphoid tissues. 4 edtion. Lyon: International agency for research on cancer, 2008: 109-147.
  • 3汤永民.流式细胞术在急性白血病微小残留病检测中的应用[J].中国实用儿科杂志,2002,17(6):370-372. 被引量:4
  • 4Buccisano F, Maurillo L, Del Principe MI, et al. Prognostic and ther- apeutic implications of minimal residual disease detection in acute myeloid leukemia [J]. Blood, 2012, 119: 332-341.
  • 5Coustan-Smith E, Sancho J, Hancock ML, et al. Chinical impor- tance of minimal residual disease in childhood acute lymphoblastic leukemia [J]. Blood, 2000, 96(8): 2691-2696.
  • 6Pawinska K, Balwierz W, Baran J, et al. Minimal resdual disease in childhood acute leukemias [J]. Przegl Lek, 2006, 63(1): 41-43.
  • 7孙楠楠,甘思林,孙慧,张秋堂,刘延方,谢新生.流式细胞术动态监测急性白血病完全缓解后微小残留病与预后的关系[J].中国实验血液学杂志,2013,21(2):339-342. 被引量:12
  • 8景清,李戈.流式细胞术检测儿童急性淋巴细胞白血病微小残留病研究进展[J].实用医院临床杂志,2007,4(6):98-100. 被引量:1

二级参考文献33

  • 1[1]Campana D.Determination of minimal residual disease in leukaemia patients[J].Br J Haematol,2003,121 (6):823-838.
  • 2[2]Szczepanski T,van der Velden VH,van Dongen JJM.Flowcytometric immunophenotyping of normal and malignant lymphocytes[J].Clin Chem Lab Med,2006,44(7):775-796.
  • 3[3]Campana D,Neale GA,Coustan-Smith E,et al.Detection of minimal residual disease in acute lymphoblastic leukemia:the St Jude experience[J].Leukemia,2001,15(2):278-279.
  • 4[4]Szczepanski T.Why and how to quantify minimal residual disease in acute lymphoblastic leukemia[J].Leukemia,2007,21 (4):622-626
  • 5[5]GAM Meale,Coustan-Smith E,P Stow,et al.Coparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia[J].Leukemia,2004,18(5):934-938.
  • 6[6]M Malec E,Bjorklund S,Soderhall J,et al.Flow cytometry and allelespecific oligonucleotide PCR are equally effective in detection of minimal residual disease in ALL[J].Leukemia,2001,15 (5):716-727.
  • 7[7]Robillard N,Cave H,Mechinaud F,et al.Four-color flow cytometry bypasses limitations of IG/TCR polymerase chain reaction for minimal residual disease detection in certain subsets of children with acute lymphoblastic leukemia[J].Haematologica,2005,90(11):1516-1523.
  • 8[8]Gunter K,Hermann K,Carmen R,et al.Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR[J].Br J Haematol,2005,128 (6):774-782.
  • 9[9]Weir EG,Cowan K,LeBeau P,et al.A limited antibody panel candistinguish B -precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry:implications for residual disease detection[J].Leukemia,1999,13(4):558-567.
  • 10[10]Lucio P,Gaipa G,van-Lochem EG,et al.BIOMED-I concerted action report:flow cytometric immunophenotyping of precursor B-ALL with standardized trip le-stainings.BIOMED-1 Concerted Action Investigation ofMinimal ResidualDisease in Acute Leukemia:International Standardization and Clinical Evaluation[J].Leukemia,2001,15 (8):1185-1192.

共引文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部